B Lymphoblastic Leukemia Minimal Residual Disease Assessment by Flow Cytometric Analysis

被引：12
作者：
Shaver, Aaron C. [1 ]
Seegmiller, Adam C. [1 ]
机构：
[1] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN USA
来源：
CLINICS IN LABORATORY MEDICINE | 2017年 / 37卷 / 04期
关键词：
Minimal residual disease; Flow cytometry; Acute lymphoblastic leukemia; HEMATOPOIETIC-CELL TRANSPLANTATION; CHRONIC LYMPHOCYTIC-LEUKEMIA; BONE-MARROW; IMMUNOPHENOTYPIC MODULATION; PROGNOSTIC-SIGNIFICANCE; CLINICAL-SIGNIFICANCE; PERIPHERAL-BLOOD; RELAPSE RISK; CHILDHOOD; CHILDREN;
D O I：
10.1016/j.cll.2017.07.005
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
Among the most thoroughly evaluated modalities for the assessment of minimal residual disease (MRD) in B acute lymphoblastic leukemia (B-ALL) is multiparameter flow cytometry. Flow cytometric evaluation of MRD for B-ALL requires complete understanding of the immunophenotype of hematogones, the normal counterpart of leukemic B lymphoblasts. Assessment of multiple flow cytometry markers, in concert with each other in multidimensional histograms, is necessary to distinguish hematogones from malignant blasts. Emerging therapies targeting CD19 and other B-cell markers can disrupt the most frequently used MRD assessment, requiring a revised approach as the use of targeted therapies becomes widespread.
引用
收藏
页码：771 / +
页数：17
相关论文
共 56 条
  • [1] [Anonymous], CYTOMETRY B
  • [2] [Anonymous], 2012, EURASIP J ADV SIG PR, DOI DOI 10.1186/1687-6180-2012-1
  • [3] Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia
    Björklund, E
    Mazur, J
    Söderhäll, S
    Porwit-MacDonald, A
    [J]. LEUKEMIA, 2003, 17 (01) : 138 - 148
  • [4] Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial
    Boettcher, Sebastian
    Ritgen, Matthias
    Fischer, Kirsten
    Stilgenbauer, Stephan
    Busch, Raymonde M.
    Fingerle-Rowson, Guenter
    Fink, Anna Maria
    Buehler, Andreas
    Zenz, Thorsten
    Wenger, Michael Karl
    Mendila, Myriam
    Wendtner, Clemens-Martin
    Eichhorst, Barbara F.
    Doehner, Hartmut
    Hallek, Michael J.
    Kneba, Michael
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (09) : 980 - 988
  • [5] Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study
    Borowitz, Michael J.
    Devidas, Meenakshi
    Hunger, Stephen P.
    Bowman, W. Paul
    Carroll, Andrew J.
    Carroll, William L.
    Linda, Stephen
    Martin, Paul L.
    Pullen, D. Jeanette
    Viswanatha, David
    Willman, Cheryl L.
    Winick, Naomi
    Camitta, Bruce M.
    [J]. BLOOD, 2008, 111 (12) : 5477 - 5485
  • [6] Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232
    Borowitz, Michael J.
    Wood, Brent L.
    Devidas, Meenakshi
    Loh, Mignon L.
    Raetz, Elizabeth A.
    Salzer, Wanda L.
    Nachman, James B.
    Carroll, Andrew J.
    Heerema, Nyla A.
    Gastier-Foster, Julie M.
    Willman, Cheryl L.
    Dai, Yunfeng
    Winick, Naomi J.
    Hunger, Stephen P.
    Carroll, William L.
    Larsen, Eric
    [J]. BLOOD, 2015, 126 (08) : 964 - 971
  • [7] Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: Implications for residual disease detection: A report from the children's oncology group
    Borowitz, MJ
    Pullen, DJ
    Winick, N
    Martin, PL
    Bowman, WP
    Camitta, B
    [J]. CYTOMETRY PART B-CLINICAL CYTOMETRY, 2005, 68B (01) : 18 - 24
  • [8] Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study
    Borowitz, MJ
    Pullen, DJ
    Shuster, JJ
    Viswanatha, D
    Montgomery, K
    Willman, CL
    Camitta, B
    [J]. LEUKEMIA, 2003, 17 (08) : 1566 - 1572
  • [9] Augmented Therapy Improves Outcome for Pediatric High Risk Acute Lymphocytic Leukemia: Results Of Children's Oncology Group Trial P9906
    Bowman, W. Paul
    Larsen, Eric L.
    Devidas, Meenakshi
    Linda, Stephen B.
    Blach, Laurie
    Carroll, Andrew J.
    Carroll, William L.
    Pullen, D. Jeanette
    Shuster, Jonathan
    Willman, Cheryl L.
    Winick, Naomi
    Camitta, Bruce M.
    Hunger, Stephen P.
    Borowitz, Michael J.
    [J]. PEDIATRIC BLOOD & CANCER, 2011, 57 (04) : 569 - 577
  • [10] Stability of leukemia-associated immunophenotypes in precursor B-lymphoblastic leukemia/lymphoma - A single institution experience
    Chen, Weina
    Karandikar, Nitin J.
    McKenna, Robert W.
    Kroft, Steven H.
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2007, 127 (01) : 39 - 46
123456